Medicines Australia welcomes industry partnership funding

Medicines Australia welcomes the Turnbull Government’s announcement of $7.4 million in funding for medical technology and pharmaceuticals industry-led projects.

MTPConnect, established under the Australian Government’s Industry Growth Centres Initiative is co-investing in projects that will help increase commercialisation of new research.

Medicines Australia is a partner in two projects that have been awarded a share of the funding:

  • the Bridge programme, led by the Bridge Consortium, will transfer practical skills on pharmaceutical commercialisation through training, including direct exposure to industry practitioners.
  • a tele-trials strategy, led by Clinical Oncology Society of Australia, will increase patient access to cancer clinical trials closer to home, whilst ensuring the proper conduct of these trials.

Medicines Australia Chief Executive Milton Catelin said “I congratulate both the Bridge Consortium and the Clinical Oncology Society of Australia on being awarded funding”.

“While Australia performs well on research excellence, evidence suggests we could do better when it comes to commercialising research outcomes.  The Bridge programme provides, through training and networking, the knowledge transfer that happens naturally in other countries,” he said.

“Investing in the tele-trials strategy is critically important because it will help patients gain access to innovative treatments not otherwise available in remote regions, and improve the lives of many Australians residing in regional areas because they will be able to stay close to home.”

“We welcome the Government’s commitment to create a highly productive commercialisation environment through investing in these very worthy and exciting projects announced today.”


James Boyce
Phone: 0423 239 265